CENTRAL NERVOUS SYSTEM LYMPHOMA

This study tests a combination of three drugs (thiotepa, pirtobrutinib, and sintilimab) in 24 people with a hard-to-treat brain lymphoma that has come back or not responded to prior treatment. The goal is to see if this approach can shrink tumors and improve survival. Participant…

This early-phase study tests whether two drugs, loncastuximab tesirine and rituximab, given after precise radiation to the brain are safe and work against central nervous system lymphoma. It includes 12 adults whose cancer has returned or who cannot take standard chemotherapy. Th…

This study tests whether combining two drugs, epcoritamab and ibrutinib, is safe for people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. About 26 adults with this rare brain cancer will take part. The main goal is to find the best do…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…

This study tests a new three-drug combination (selinexor, methotrexate, and rituximab) for adults with central nervous system lymphoma that has returned or not responded to prior treatment. About 30 participants will receive the drugs to find the safest dose and see how well it s…

This study tracks memory and thinking changes in 100 adults with blood cancers (like lymphoma or leukemia) who receive whole brain radiation. Researchers will test cognitive skills over time to understand the treatment's effects on the brain. The goal is to learn more, not to tes…

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…